Results for tag: "Afstyla"

Afstyla is a brand of hematological drugs used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. The drug is a recombinant factor VIII (rFVIII) therapy, which is a type of protein replacement therapy. Afstyla is a long-acting, extended half-life therapy, meaning it can be administered less frequently than other treatments. It is administered via intravenous injection and is designed to reduce the number of injections needed to maintain adequate clotting factor levels. Afstyla is a relatively new drug, having been approved by the US Food and Drug Administration in 2017. It is currently marketed by Swedish pharmaceutical company, CSL Behring. Other companies in the market include Novo Nordisk, Pfizer, and Bayer. Show Less Read more